27.04.2011 • News

Ashland Shares Rise After Profit Widely Beats Expectations

Chemical maker Ashland posted a better-than-expected quarterly profit as it raised prices to counter rising raw material costs, sending its shares up more than 4% in premarket trading.

The company makes a wide range of specialty chemicals, including Valvoline oil as well as materials for the packaging and water purification industries. Its improving results offer a small hint on broader economic recovery.

The company's chief executive, James O'Brien, recently underwent surgery to fix a perforated colon. Ashland said last month that O'Brien would be away for up to three months. O'Brien is working on a limited basis after his surgery, a spokesman said on Tuesday.

For the second quarter ended on March 31, Ashland's net income came to $353 million, or $4.39 per share, including a $231 million gain from the sale of its distribution unit to private equity firm TPG Capital for $979 million cash. Excluding that and other one-time items, Ashland posted earnings of 86 cents per share. By that measure, analysts expected 77 cents, according to Thomson Reuters I/B/E/S. Year-earlier net income was $22 million, or 27 cents per share.

Revenue rose 9% to $1.56 billion. Analysts expected $1.49 billion. The cost of sales rose 14% to $1.14 billion.

Shares of Ashland were up 4.3% to $59.50 in trading before the market opened. The stock price has ranged from $42.77 to $63.69 in the past 52 weeks.

Company

Logo:

Ashland

500 Hercules Road Building 8145
19808 Wilmington, DE
US

Company contact







Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.